Bariatric Surgery Lowers Risk of Serious Heart Problems and Death in Patients Obstructive Sleep Apnea

Bariatric surgery, which helps people lose weight, appears to significantly lower the risk of serious heart problems and death for those who are obese and suffer from moderate-to-severe sleep apnea, according to a recent study. This research, known as the MOSAIC study, found that people who had the surgery reduced their risk of major cardiovascular issues by 42% and their overall risk of death by 37% compared to those who didn’t undergo the surgery. Read more

Conversion of Sleeve Gastrectomy to Gastric Bypass: Improved GERD Management and Weight Loss

Sleeve Gastrectomy has become a widely adopted procedure for weight loss. However, its success is sometimes overshadowed by complications such as postoperative gastroesophageal reflux disease (GERD) and weight recurrence. As a result, converting Sleeve Gastrectomy to Roux-en-Y Gastric Bypass has emerged as a potential solution. To explore the effectiveness of this conversion, a comprehensive study was conducted across 41 hospitals in Michigan from 2014 to 2022.

The study highlights several significant benefits of converting sleeve gastrectomy to Roux-en-y Gastric Bypass:

Improved GERD Symptoms

One of the primary motivations for converting Sleeve Gastrectomy to Roux-en-Y Gastric Bypass is the management of GERD. Dr. Alexander Abkin, a bariatric surgeon based in New Jersey, emphasizes the effectiveness of this approach. “The conversion to Gastric Bypass can drastically reduce GERD symptoms. Our patients frequently report substantial relief after the procedure,” says Dr. Abkin. The study supports this, with GERD-HRQL scores dropping significantly from 24.6 to 6.6. Additionally, the need for anti-reflux medication decreased from 74% to 27% within a year of conversion.

Significant Weight Loss

Weight management is another crucial aspect where conversion shows notable improvement. Patients experienced an average weight loss of 68.4 pounds, which translates to a 24.3% reduction in total body weight and a 51.5% decrease in excess body weight. According to Dr. Abkin, “The conversion not only addresses GERD but also substantially aids in further weight reduction, which can be crucial for long-term success in managing obesity.”

The findings from this large-scale study demonstrate that converting Sleeve Gastrectomy to Roux-en-Y Gastric Bypass offers significant benefits, particularly in managing GERD and achieving substantial weight loss. The procedure has proven effective in alleviating GERD symptoms and reducing the reliance on anti-reflux medications. However, as Dr. Abkin advises, “Every patient’s case is unique, and the decision to convert should be tailored to the individual’s overall health profile and comorbidities.”

This research underscores the importance of personalized treatment strategies in bariatric surgery and offers valuable insights for patients and surgeons considering conversion from Sleeve Gastrectomy to Roux-en-Y Gastric Bypass.

Long-Term Success of Roux-en-Y Gastric Bypass: What You Need to Know

If you’ve been considering Roux-en-Y Gastric Bypass (RYGB) for weight loss, you might wonder how effective it is in the long run. A recent study looked at patients who had the surgery between 2008 and 2009 and followed them for up to 15 years. Here’s what they found, with insights from Dr. Alexander Abkin, a bariatric surgeon from New Jersey.

Long-Term Weight Loss

The study included 264 patients, mostly women, and assessed how well they maintained weight loss over 15 years. The results were promising. On average, patients lost about 31.5% of their total body weight in the first year, and they managed to keep losing more than 20% of their body weight throughout the follow-up period.

Dr. Abkin explains, “Roux-en-Y Gastric Bypass is known for its effectiveness in the short term, but this study really shows its long-term potential. Patients can maintain significant weight loss over many years, which is crucial for long-term success.”

Improvement in Health Conditions

The surgery didn’t just help with weight loss—it also improved several obesity-related health conditions. For example, about 61% of patients saw their type 2 diabetes go into remission, 47% saw improvements in their cholesterol levels, and 40% had their high blood pressure resolved. However, some conditions did return over time, with 24% of patients experiencing a return of diabetes and 18% seeing their high blood pressure come back.

Dr. Abkin adds, “One of the great benefits of Roux-en-Y Gastric Bypass is its ability to significantly improve or resolve health conditions related to obesity. However, it’s important to keep monitoring and managing these conditions, as some patients might experience a recurrence.”

Challenges and Considerations

The study also noted that about 51% of patients saw some weight regain over 15 years. Factors like higher initial body mass index and having type 2 diabetes before the surgery were linked to a higher chance of weight regain.

Dr. Abkin advises, “While Roux-en-Y Gastric Bypass can offer lasting results, it’s not a cure-all. Maintaining weight loss and health improvements requires ongoing effort and regular check-ups. Understanding the factors that contribute to weight regain can help in managing and overcoming these challenges.”

Conclusion

Overall, the study confirms that laparoscopic Roux-en-Y Gastric Bypass offers significant and lasting benefits for weight loss and improving obesity-related health conditions. Dr. Abkin sums it up: “Roux-en-Y Gastric Bypass remains a promising option for long-term weight management and health improvement. For those considering this surgery, it’s important to be aware of both its benefits and the need for long-term commitment to maintain results.”

This research highlights the effectiveness of Roux-en-Y Gastric Bypass over a lengthy period, offering valuable insights for anyone looking into weight loss surgery options.

Non-Surgical Weight Loss

Weight Loss Surgery vs. Medication: What’s Better for Long-Term Health?

New research reveals that weight loss surgery, specifically Bariatric Metabolic Surgery (BMS), can provide a significant survival advantage over the popular diabetes medication class, GLP-1 receptor agonists (GLP-1 RAs), for adults with obesity and diabetes of up to 10 years. Read more

Cardiovascular Disease Expected to Increase in the Coming Decades

Heart disease has held the title of the world’s leading cause of death for over a century. Unfortunately, the future does not seem to offer any relief from this statistic. Read more

Dr. Abkin Joins New York Bariatric Group

We’re thrilled to announce some exciting news! Advanced Laparoscopic Surgeons of Morris has officially joined New York Bariatric Group (NYBG), the nation’s leading provider of bariatric services. This collaboration marks a significant stride in our dedication to delivering cutting-edge surgical techniques and exceptional patient care.

Dr. Alexander Abkin and his team from Advanced Laparoscopic Surgeons of Morris will now be part of the esteemed NYBG team, which boasts 25 renowned bariatric surgeons. NYBG is well known for its patient-centered approach to weight-loss, offering a comprehensive range of services including expedited one-day presurgical assessments, aftercare programs, support groups, and nutritional guidance.

In addition, the introduction of ambulatory surgery centers (ASC) will greatly enhance the patient experience, providing a state-of-the-art facility for same-day surgical procedures. These ASCs offer a superior alternative to traditional hospital stays, ensuring a safe and comfortable surgical journey.

We’re genuinely excited about this partnership and the opportunities it presents to enhance our service to you. If you have any questions or wish to schedule an appointment, please call 973-410-9700.

Sincerely,

Dr. Alexander Abkin
Advanced Laparoscopic Surgeons of Morris

As Zepbound Shortage Grows, Eli Lilly Says No Immediate End Is In Sight

As the demand for weight loss medications surges, the availability of Zepbound, manufactured by Eli Lilly, faces significant shortages, with no immediate solution in sight. The FDA approved Zepbound in November, offering a new option for weight loss alongside Novo Nordisk’s Wegovy. However, despite earlier assurances from Lilly’s CEO, Dave Ricks, shortages have become widespread just months after approval. Read more

Why Bariatric Surgery May Be Better Than Wegovy and Zepbound

Within the rise in popularity of weight loss medications like Zepbound and Wegovy is a less-noticed phenomenon: Some patients don’t lose much weight on them. Read more

Understanding Gastric Bypass: A Key to Diabetes Remission

New research sheds light on the effectiveness of gastric bypass surgery in maintaining remission of type 2 diabetes, even if patients regain weight over time. Dr. Alexander Abkin, a leading bariatric surgeon in New Jersey, helps break down the findings for us. Read more

Why Mindful Eating is Better than Dieting

Snack fever sets in — do you succumb, or shake it off?

For those who can’t seem to quit noshing on junk, experts say they have just the thing to break the cycle — a practice known as mindful eating. Read more